Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ$5.03
Market Cap
$749.88M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
355 of 924
Rank in Industry
208 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
XERS Insider Trading Activity
XERS Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $30,595 | 3 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Schmid John P. | director | 3 | $30,595 | 0 | $0 | $30,595 |
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's …
Insider Activity of Xeris Biopharma Holdings, Inc.
Over the last 12 months, insiders at Xeris Biopharma Holdings, Inc. have bought $30,595 and sold $0 worth of Xeris Biopharma Holdings, Inc. stock.
On average, over the past 5 years, insiders at Xeris Biopharma Holdings, Inc. have bought $316,957 and sold $151,244 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Schmid John P. (director) — $30,595.
The last purchase of 4,515 shares for transaction amount of $10,147 was made by Schmid John P. (director) on 2024‑08‑12.
List of Insider Buy and Sell Transactions, Xeris Biopharma Holdings, Inc.
| 2024-08-12 | Schmid John P. | director | 4,515 0.003% | $2.25 | $10,147 | +44.22% | ||
| 2024-08-09 | Schmid John P. | director | 4,285 0.0029% | $2.37 | $10,134 | +39.66% | ||
| 2024-05-10 | Schmid John P. | director | 5,400 0.004% | $1.91 | $10,314 | +68.18% | ||
| 2024-03-14 | Schmid John P. | director | 4,500 0.0032% | $2.16 | $9,720 | +32.63% | ||
| 2023-11-27 | SHERMAN JEFFREY W | director | 5,400 0.004% | $1.87 | $10,098 | +32.07% | ||
| 2023-11-20 | Pieper Steven | See Remarks | 28,000 0.0218% | $1.95 | $54,600 | +32.42% | ||
| 2023-11-20 | HALKUFF DAWN | director | 5,410 0.004% | $1.84 | $9,954 | +32.42% | ||
| 2023-11-17 | Shannon John Patrick Jr | See Remarks | 30,769 0.0206% | $1.64 | $50,400 | +34.46% | ||
| 2023-11-16 | Schmid John P. | director | 6,500 0.0045% | $1.51 | $9,815 | +51.59% | ||
| 2023-11-14 | PERSKY MARLA | director | 6,370 0.0047% | $1.58 | $10,058 | +52.24% | ||
| 2023-08-09 | Edick Paul R | See Remarks | 10,000 0.0073% | $2.38 | $23,794 | -9.79% | ||
| 2022-12-13 | Edick Paul R | See Remarks | 20,000 0.0152% | $1.45 | $29,000 | +34.75% | ||
| 2022-05-12 | Edick Paul R | See Remarks | 100,000 0.0681% | $1.40 | $140,380 | +0.66% | ||
| 2022-02-22 | Sale | PRESTRELSKI STEVEN | Chief Scientific Officer | 11,228 0.0085% | $2.42 | $27,158 | -32.35% | |
| 2021-11-15 | Edick Paul R | See Remarks | 20,000 0.0151% | $2.28 | $45,664 | -17.14% | ||
| 2021-11-12 | Shannon John Patrick Jr | See Remarks | 60,000 0.0484% | $2.10 | $126,000 | -2.80% | ||
| 2021-11-11 | Edick Paul R | See Remarks | 200,000 0.1644% | $2.08 | $415,760 | 0.00% | ||
| 2021-11-11 | Shannon John Patrick Jr | See Remarks | 40,000 0.033% | $2.09 | $83,500 | 0.00% | ||
| 2021-11-10 | Pieper Steven | See Remarks | 25,000 0.0216% | $2.00 | $49,918 | +9.47% | ||
| 2021-04-12 | Sale | PRESTRELSKI STEVEN | Chief Scientific Officer | 10,000 0.0156% | $4.07 | $40,725 | -34.99% |
Total: 58
*Gray background shows transactions not older than one year
Insider Historical Profitability
14.31%
| Schmid John P. | director | 25200 0.0169% | $126,756.00 | 5 | 0 | +42.11% |
| Redmile Group, LLC | 10 percent owner | 3000642 2.0128% | $15.09M | 2 | 0 | <0.0001% |
| Edick Paul R | See Remarks | 2288064 1.5348% | $11.51M | 10 | 0 | +1.38% |
| Palmetto Partners, Ltd. | 10 percent owner | 2110061 1.4154% | $10.61M | 1 | 0 | <0.0001% |
| Shannon John Patrick Jr | See Remarks | 1408575 0.9448% | $7.09M | 6 | 0 | +19.99% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$3,596,906 | 112 | 13.42% | $635.29M | |
$36,510,315 | 95 | 8.95% | $617.34M | |
$7,929,017 | 58 | 21.56% | $788.11M | |
$97,176 | 41 | 42.84% | $782.59M | |
$94,912,877 | 34 | -7.15% | $620.95M |
XERS Institutional Investors: Active Positions
| Increased Positions | 90 | +68.7% | 10M | +16.26% |
| Decreased Positions | 45 | -34.35% | 9M | -13.7% |
| New Positions | 32 | New | 3M | New |
| Sold Out Positions | 14 | Sold Out | 1M | Sold Out |
| Total Postitions | 176 | +34.35% | 65M | +2.57% |
XERS Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $52,158.00 | 7.03% | 10.82M | +87,097 | +0.81% | 2024-12-31 |
| Vanguard Group Inc | $38,073.00 | 5.13% | 7.9M | +133,738 | +1.72% | 2024-12-31 |
| Geode Capital Management, Llc | $16,154.00 | 2.18% | 3.35M | +17,956 | +0.54% | 2024-12-31 |
| State Street Corp | $16,108.00 | 2.17% | 3.34M | +137,156 | +4.28% | 2024-12-31 |
| Rosalind Advisors, Inc. | $14,966.00 | 2.02% | 3.1M | 0 | 0% | 2024-12-31 |
| Morgan Stanley | $13,870.00 | 1.87% | 2.88M | +523,208 | +22.22% | 2024-12-31 |
| Aigh Capital Management Llc | $12,411.00 | 1.67% | 2.57M | +389,192 | +17.81% | 2024-12-31 |
| Renaissance Technologies Llc | $10,116.00 | 1.36% | 2.1M | +500,120 | +31.28% | 2024-12-31 |
| Caxton Corp | $9,713.00 | 1.31% | 2.02M | -3M | -60.59% | 2024-12-31 |
| Millennium Management Llc | $9,392.00 | 1.27% | 1.95M | +502,853 | +34.78% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.